## Daniel B Mark

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/641498/publications.pdf

Version: 2024-02-01

437 papers

64,443 citations

105 h-index 227 g-index

448 all docs 448 docs citations

times ranked

448

44453 citing authors

#	Article	IF	CITATIONS
1	MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS. , 1996, 15, 361-387.		7,967
2	Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure. New England Journal of Medicine, 2005, 352, 225-237.	13.9	5,972
3	Longitudinal Assessment of Neurocognitive Function after Coronary-Artery Bypass Surgery. New England Journal of Medicine, 2001, 344, 395-402.	13.9	2,259
4	ACC/AHA 2002 Guideline Update for Exercise Testing: Summary Article. Circulation, 2002, 106, 1883-1892.	1.6	1,525
5	Initial Invasive or Conservative Strategy for Stable Coronary Disease. New England Journal of Medicine, 2020, 382, 1395-1407.	13.9	1,508
6	A brief self-administered questionnaire to determine functional capacity (The Duke Activity Status) Tj ETQq0 0 0	rgBT <sub>/</sub> /Ove	rlock 10 Tf 50 1,422
7	Prognostic Importance of Defibrillator Shocks in Patients with Heart Failure. New England Journal of Medicine, 2008, 359, 1009-1017.	13.9	1,282
8	Depression and Coronary Heart Disease. Circulation, 2008, 118, 1768-1775.	1.6	1,215
9	Outcomes of Anatomical versus Functional Testing for Coronary Artery Disease. New England Journal of Medicine, 2015, 372, 1291-1300.	13.9	1,179
10	ACC/AHA 2002 guideline update for exercise testing: summary article. Journal of the American College of Cardiology, 2002, 40, 1531-1540.	1.2	1,136
11	Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2019, 321, 1261.	3.8	953
12	ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 Appropriate Use Criteria for Cardiac Computed Tomography. Journal of the American College of Cardiology, 2010, 56, 1864-1894.	1.2	886
13	Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation. JAMA - Journal of the American Medical Association, 2007, 297, 159.	3.8	778
14	Prognostic Value of a Treadmill Exercise Score in Outpatients with Suspected Coronary Artery Disease. New England Journal of Medicine, 1991, 325, 849-853.	13.9	751
15	A Comparison of Directional Atherectomy with Coronary Angioplasty in Patients with Coronary Artery Disease. New England Journal of Medicine, 1993, 329, 221-227.	13.9	680
16	Coronary Intervention for Persistent Occlusion after Myocardial Infarction. New England Journal of Medicine, 2006, 355, 2395-2407.	13.9	635
17	management and outcomes of patients with acute coronary syndromes 31 This document was approved by the American College of Cardiology Board of Trustees in November 2001.32 When citing this document, the American College of Cardiology would appreciate the following citation format: Cannon CP, Battler A, Brinds RG, Cox JL, Ellis SG, Every NR, Flaherty JT, Harrington RA, Krumholz HM,	1.2	621
18	Simpons ML, Van de Werf Fl), Weintraub, Journal of the American College of Cardiology, 2001, 30, 3114.7 Depression as a risk factor for mortality after coronary artery bypass surgery. Lancet, The, 2003, 362, 604-609.	6.3	577

#	Article	IF	CITATIONS
19	Exercise Treadmill Score for Predicting Prognosis in Coronary Artery Disease. Annals of Internal Medicine, 1987, 106, 793.	2.0	554
20	Racial Variation in the Use of Coronary-Revascularization Procedures — Are the Differences Real? Do They Matter?. New England Journal of Medicine, 1997, 336, 480-486.	13.9	531
21	Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial Infarction. New England Journal of Medicine, 1995, 332, 1418-1424.	13.9	522
22	Depression and Long-Term Mortality Risk in Patients With Coronary Artery Disease * *This study was supported in part by grants P01 HL36587, R01 HL43028, R01 HL44998, R01 HL45702, and R01 HL49572 from the National Heart, Lung and Blood Institute; and AG-09276, AG09663, 5P60 AG-11268, and P02 AG-12058 from the National Institute on Aging American Journal of Cardiology, 1996, 78, 613-617.	0.7	461
23	Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2005, 46, 2153-2167.	1.2	437
24	Prognostic value of a coronary artery jeopardy score. Journal of the American College of Cardiology, 1985, 5, 1055-1063.	1.2	425
25	Palliative Care in Heart Failure. Journal of the American College of Cardiology, 2017, 70, 331-341.	1.2	425
26	Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2019, 321, 1275.	3.8	388
27	Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2017, 318, 713.	3.8	386
28	ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 Appropriate Use Criteria for Cardiac Computed Tomography. Circulation, 2010, 122, e525-55.	1.6	357
29	ACC/AHA Statement on Cost/Value Methodology in ClinicalÂPractice Guidelines and Performance Measures. Journal of the American College of Cardiology, 2014, 63, 2304-2322.	1.2	353
30	Regional Variation across the United States in the Management of Acute Myocardial Infarction. New England Journal of Medicine, 1995, 333, 565-572.	13.9	351
31	Use of High-Risk Coronary Atherosclerotic Plaque Detection for Risk Stratification of Patients With Stable Chest Pain. JAMA Cardiology, 2018, 3, 144.	3.0	349
32	Representation of Women in Randomized Clinical Trials of Cardiovascular Disease Prevention. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 135-142.	0.9	345
33	Outcome of Acute Myocardial Infarction According to the Specialty of the Admitting Physician. New England Journal of Medicine, 1996, 335, 1880-1887.	13.9	342
34	Prognostic Value of Noninvasive Cardiovascular Testing in Patients With Stable Chest Pain. Circulation, 2017, 135, 2320-2332.	1.6	336
35	ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures. Circulation, 2014, 129, 2329-2345.	1.6	329
36	Use of Medical Resources and Quality of Life after Acute Myocardial Infarction in Canada and the United States. New England Journal of Medicine, 1994, 331, 1130-1135.	13.9	322

#	Article	IF	Citations
37	Report of the Substudy Assessing the Impact of Neurocognitive Function on Quality of Life 5 Years After Cardiac Surgery. Stroke, 2001, 32, 2874-2881.	1.0	319
38	Factors affecting sensitivity and specificity of exercise electrocardiography. American Journal of Medicine, 1984, 77, 64-71.	0.6	318
39	Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. Lancet, The, 1999, 354, 2019-2024.	6.3	316
40	Management of Coronary Disease in Patients with Advanced Kidney Disease. New England Journal of Medicine, 2020, 382, 1608-1618.	13.9	310
41	Characteristics of Socially Isolated Patients With Coronary Artery Disease Who Are at Elevated Risk for Mortality. Psychosomatic Medicine, 2001, 63, 267-272.	1.3	304
42	Medical Care Costs and Quality of Life after Randomization to Coronary Angioplasty or Coronary Bypass Surgery. New England Journal of Medicine, 1997, 336, 92-99.	13.9	303
43	Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidney International, 2001, 60, 1490-1497.	2.6	294
44	Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. New England Journal of Medicine, 2020, 382, 1408-1419.	13.9	287
45	The Relation between the Volume of Coronary Angioplasty Procedures at Hospitals Treating Medicare Beneficiaries and Short-Term Mortality. New England Journal of Medicine, 1994, 331, 1625-1629.	13.9	284
46	Restenosis after coronary angioplasty: An overview. Journal of the American College of Cardiology, 1991, 17, 2-13.	1.2	275
47	Central nervous system injury associated with cardiac surgery. Lancet, The, 2006, 368, 694-703.	6.3	270
48	Use of a Prognostic Treadmill Score in Identifying Diagnostic Coronary Disease Subgroups. Circulation, 1998, 98, 1622-1630.	1.6	264
49	Cardiac rupture, mortality and the timing of thrombolytic therapy: A meta-analysis. Journal of the American College of Cardiology, 1990, 16, 359-367.	1.2	261
50	Home Use of Automated External Defibrillators for Sudden Cardiac Arrest. New England Journal of Medicine, 2008, 358, 1793-1804.	13.9	254
51	ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 Expert Consensus Document on Coronary Computed Tomographic Angiography. Circulation, 2010, 121, 2509-2543.	1.6	247
52	ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 Expert Consensus Document on Coronary Computed Tomographic Angiography. Journal of the American College of Cardiology, 2010, 55, 2663-2699.	1.2	244
53	Cost-Effectiveness of Defibrillator Therapy or Amiodarone in Chronic Stable Heart Failure. Circulation, 2006, 114, 135-142.	1.6	239
54	The Primary and Secondary Prevention of Coronary Artery Disease. Chest, 2008, 133, 776S-814S.	0.4	234

#	Article	IF	CITATIONS
55	Quality of Life with Defibrillator Therapy or Amiodarone in Heart Failure. New England Journal of Medicine, 2008, 359, 999-1008.	13.9	230
56	Prognostic implications of angiographically normal and insignificantly narrowed coronary arteries. American Journal of Cardiology, 1986, 58, 1181-1187.	0.7	229
57	Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. Journal of Thoracic and Cardiovascular Surgery, 1996, 111, 1013-1025.	0.4	228
58	Relationship Between Diabetes Mellitus and Long-term Survival After Coronary Bypass and Angioplasty. Circulation, 1997, 96, 2551-2556.	1.6	225
59	Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure. Circulation, 2021, 143, 1377-1390.	1.6	223
60	Chronic Kidney Disease, Mortality, and Treatment Strategies among Patients with Clinically Significant Coronary Artery Disease. Journal of the American Society of Nephrology: JASN, 2003, 14, 2373-2380.	3.0	213
61	Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure. Circulation, 2009, 120, 2170-2176.	1.6	213
62	Effect of Disodium EDTA Chelation Regimen on Cardiovascular Events in Patients With Previous Myocardial Infarction. JAMA - Journal of the American Medical Association, 2013, 309, 1241.	3.8	209
63	Non–Evidence-Based ICD Implantations in the United States. JAMA - Journal of the American Medical Association, 2011, 305, 43.	3.8	207
64	Value of exercise treadmill testing in women. Journal of the American College of Cardiology, 1998, 32, 1657-1664.	1.2	205
65	Outcomes of Coronary Artery Bypass Graft Surgery in 24 461 Patients Aged 80 Years or Older. Circulation, 1995, 92, 85-91.	1.6	205
66	Absence of Sex Bias in the Referral of Patients for Cardiac Catheterization. New England Journal of Medicine, 1994, 330, 1101-1106.	13.9	203
67	Maximizing Survival Benefit With Primary Prevention Implantable Cardioverter-Defibrillator Therapy in a Heart Failure Population. Circulation, 2009, 120, 835-842.	1.6	202
68	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. American Heart Journal, 2018, 201, 124-135.	1.2	202
69	Prognosis in cardiogenic shock after acute myocardial infarction in the intervencional era. Journal of the American College of Cardiology, 1992, 20, 1482-1489.	1.2	198
70	The effects of New York's bypass surgery provider profiling on access to care and patient outcomes in the elderly. Journal of the American College of Cardiology, 1998, 32, 993-999.	1.2	195
71	Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2005, 46, 2168-2182.	1.2	193
72	ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 Appropriate Use Criteria for Cardiac Computed Tomography. Journal of Cardiovascular Computed Tomography, 2010, 4, 407.e1-407.e33.	0.7	193

#	Article	IF	Citations
73	A National Survey of Provisions in Clinical-Trial Agreements between Medical Schools and Industry Sponsors. New England Journal of Medicine, 2002, 347, 1335-1341.	13.9	190
74	Educational and Psychological Interventions to Improve Outcomes for Recipients of Implantable Cardioverter Defibrillators and Their Families. Circulation, 2012, 126, 2146-2172.	1.6	187
75	Comparing risk-adjustment methods for provider profiling. , 1998, 16, 2645-2664.		186
76	Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy. New England Journal of Medicine, 2019, 381, 739-748.	13.9	186
77	The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. Journal of Thoracic and Cardiovascular Surgery, 2007, 134, 1540-1547.e4.	0.4	182
78	Depressive Symptoms and Survival of Patients With Coronary Artery Disease. Psychosomatic Medicine, 2000, 62, 790-795.	1.3	180
79	The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. Journal of the American College of Cardiology, 2004, 43, 576-582.	1.2	179
80	Relationship Between Physician and Hospital Coronary Angioplasty Volume and Outcome in Elderly Patients. Circulation, 1997, 95, 2485-2491.	1.6	176
81	Role of Microvolt T-Wave Alternans in Assessment of Arrhythmia Vulnerability Among Patients With Heart Failure and Systolic Dysfunction. Circulation, 2008, 118, 2022-2028.	1.6	174
82	Association of Neurocognitive Function and Quality of Life 1 Year After Coronary Artery Bypass Graft (CABG) Surgery. Psychosomatic Medicine, 2006, 68, 369-375.	1.3	170
83	Economic Assessment of Low-Molecular-Weight Heparin (Enoxaparin) Versus Unfractionated Heparin in Acute Coronary Syndrome Patients. Circulation, 1998, 97, 1702-1707.	1.6	163
84	Noninvasive FFR Derived From CoronaryÂCT Angiography. JACC: Cardiovascular Imaging, 2017, 10, 1350-1358.	2.3	162
85	Outcome in suspected acute myocardial infarction with normal or minimally abnormal admission electrocardiographic findings. American Journal of Cardiology, 1987, 60, 766-770.	0.7	157
86	Risk of Thromboembolism in Heart Failure. Circulation, 2007, 115, 2637-2641.	1.6	157
87	Comparison of predictions based on observational data with the results of randomized controlled clinical trials of coronary artery bypass surgery. Journal of the American College of Cardiology, 1988, 11, 237-245.	1.2	153
88	Importance of clinical measures of ischemia in the prognosis of patients with documented coronary artery disease. Journal of the American College of Cardiology, 1988, 11, 20-26.	1.2	152
89	Evolution of the coronary care unit: Clinical characteristics and temporal trends in healthcare delivery and outcomes*. Critical Care Medicine, 2010, 38, 375-381.	0.4	151
90	Music, imagery, touch, and prayer as adjuncts to interventional cardiac care: the Monitoring and Actualisation of Noetic Trainings (MANTRA) II randomised study. Lancet, The, 2005, 366, 211-217.	6.3	147

#	Article	IF	Citations
91	Heavy Metals, Cardiovascular Disease, andÂthe Unexpected Benefits of Chelation Therapy. Journal of the American College of Cardiology, 2016, 67, 2411-2418.	1.2	145
92	Relation of clinical and angiographic factors to functional capacity as measured by the Duke Activity Status Index. American Journal of Cardiology, 1991, 68, 973-975.	0.7	141
93	No Benefit From Defibrillation Threshold Testing in the SCD-HeFT (Sudden Cardiac Death in Heart) Tj ETQq $1\ 1\ 0.7$	784314 rg 1.2	:BT <sub>1</sub> Overlock
94	Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity. Circulation, 2021, 144, 1024-1038.	1.6	140
95	Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: Insights from the coronary angioplasty versus excisional atherectomy trial (CAVEAT). Journal of the American College of Cardiology, 1995, 25, 1693-1699.	1.2	137
96	Gentamicin–Collagen Sponge for Infection Prophylaxis in Colorectal Surgery. New England Journal of Medicine, 2010, 363, 1038-1049.	13.9	135
97	Cost Effectiveness of Early Discharge after Uncomplicated Acute Myocardial Infarction. New England Journal of Medicine, 2000, 342, 749-755.	13.9	127
98	The Value of Estimated Functional Capacity in Estimating Outcome. Journal of the American College of Cardiology, 2006, 47, S36-S43.	1,2	124
99	Job Strain and the Prevalence and Outcome of Coronary Artery Disease. Circulation, 1995, 92, 327-333.	1.6	124
100	Importance of Baseline Functional and Socioeconomic Factors for Participation in Cardiac Rehabilitation. American Journal of Cardiology, 1995, 76, 36-39.	0.7	123
101	Effect of an Implantable Gentamicin-Collagen Sponge on Sternal Wound Infections Following Cardiac Surgery <subtitle>A Randomized Trial</subtitle> . JAMA - Journal of the American Medical Association, 2010, 304, 755.	3.8	121
102	Usefulness of psychosocial treatment of mental stress-induced myocardial ischemia in men. American Journal of Cardiology, 2002, 89, 164-168.	0.7	120
103	Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic DrugÂTherapy in the CABANA Trial. Journal of the American College of Cardiology, 2020, 75, 3105-3118.	1.2	119
104	Economic Assessment of Platelet Glycoprotein Ilb/IIIa Inhibition for Prevention of Ischemic Complications of High-Risk Coronary Angioplasty. Circulation, 1996, 94, 629-635.	1.6	119
105	Early discharge in the thrombolytic era: An analysis of criteria for uncomplicated infarction from the global utilization of streptokinase and t-PA for occluded coronary arteries (GUSTO) trial. Journal of the American College of Cardiology, 1996, 27, 625-632.	1.2	117
106	Outcomes of noncardiac surgery after coronary bypass surgery or coronary angioplasty in the Bypass Angioplasty Revascularization Investigation (BARI). American Journal of Medicine, 2001, 110, 260-266.	0.6	111
107	Sex Differences in Demographics, Risk Factors, Presentation, and Noninvasive Testing in Stable Outpatients With Suspected Coronary Artery Disease. JACC: Cardiovascular Imaging, 2016, 9, 337-346.	2.3	111
108	Hostility as a Predictor of Survival in Patients With Coronary Artery Disease. Psychosomatic Medicine, 2004, 66, 629-632.	1.3	110

#	Article	IF	CITATIONS
109	The Association Between Self-Rated Health and Mortality in a Well-Characterized Sample of Coronary Artery Disease Patients. Medical Care, 1999, 37, 1226-1236.	1.1	109
110	Costs for Heart Failure With Normal vs Reduced Ejection Fraction. Archives of Internal Medicine, 2006, 166, 112.	4.3	108
111	Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design. American Heart Journal, 2018, 199, 192-199.	1.2	107
112	Cost-Effectiveness of Platelet Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Nonâ∈"ST-Elevation Acute Coronary Syndromes. Circulation, 2000, 101, 366-371.	1.6	106
113	Syncope Predicts the Outcome of Cardiomyopathy Patients. Journal of the American College of Cardiology, 2008, 51, 1277-1282.	1.2	106
114	Rationale and Design of theÂGUIDE-ITÂStudy. JACC: Heart Failure, 2014, 2, 457-465.	1.9	106
115	Detection of restenosis after elective percutaneous transluminal coronary angioplasty using the exercise treadmill test. American Journal of Cardiology, 1990, 65, 28-34.	0.7	105
116	Thrombotic and cardiovascular complications related to nonionic contrast media during cardiac catheterization: Analysis of 8,517 patients. American Journal of Cardiology, 1990, 65, 1481-1484.	0.7	105
117	Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). Journal of the American College of Cardiology, 1995, 26, 922-930.	1.2	105
118	Clinical and Economic Implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Annals of Internal Medicine, 2005, 142, 593.	2.0	105
119	Survival and cardiac event rates in the first year after emergency coronary angioplasty for acute myocardial infarction. Journal of the American College of Cardiology, 1988, 11, 1141-1149.	1.2	104
120	Medical Economics and the Assessment of Value in Cardiovascular Medicine: Part I. Circulation, 2002, 106, 516-520.	1.6	104
121	PROspective Multicenter Imaging Study for Evaluation of chest pain: Rationale and design of the PROMISE trial. American Heart Journal, 2014, 167, 796-803.e1.	1.2	104
122	Comparison of analytic models for estimating the effect of clinical factors on the cost of coronary artery bypass graft surgery. Journal of Clinical Epidemiology, 1993, 46, 261-271.	2.4	103
123	Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. JAMA Cardiology, 2019, 4, 273.	3.0	100
124	2020 ACC/AHA guideline for the management of patients with valvular heart disease. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, e183-e353.	0.4	100
125	Clopidogrel use and bleeding after coronary artery bypass graft surgery. American Heart Journal, 2008, 156, 886-892.	1.2	97
126	Exercise Capacity. Circulation, 2003, 108, 1534-1536.	1.6	96

#	Article	IF	Citations
127	Thyroid Function in Heart Failure and ImpactÂonÂMortality. JACC: Heart Failure, 2013, 1, 48-55.	1.9	96
128	Comparison of time domain and frequency domain variables from the signal-averaged electrocardiogram: A multivariable analysis. Journal of the American College of Cardiology, 1988, 11, 1041-1051.	1.2	94
129	Social Support and Hostility as Predictors of Depressive Symptoms in Cardiac Patients One Month After Hospitalization. Psychosomatic Medicine, 1998, 60, 707-713.	1.3	93
130	Medical Costs and Quality of Life 10 to 12 Years After Randomization to Angioplasty or Bypass Surgery for Multivessel Coronary Artery Disease. Circulation, 2004, 110, 1960-1966.	1.6	93
131	Natriuretic peptides in the diagnosis and management of heart failure. Cmaj, 2006, 175, 611-617.	0.9	91
132	Long-term costs and resource use in elderly participants with congestive heart failure in the Cardiovascular Health Study. American Heart Journal, 2007, 153, 245-252.	1.2	91
133	Survival of Patients Receiving a Primary Prevention Implantable Cardioverter-Defibrillator in Clinical Practice vs Clinical Trials. JAMA - Journal of the American Medical Association, 2013, 309, 55.	3.8	90
134	Survival Benefit of the Primary Prevention Implantable Cardioverter-Defibrillator Among Older Patients. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 179-186.	0.9	90
135	Estimating the likelihood of severe coronary artery disease. American Journal of Medicine, 1991, 90, 553-562.	0.6	89
136	Ergonovine maleate testing during cardiac catheterization: A 10-year perspective in 3,447 patients without significant coronary artery disease or Prinzmetal's variant angina. Journal of the American College of Cardiology, 1992, 20, 107-111.	1.2	89
137	Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death in CKD: A Meta-analysis of Patient-Level Data From 3 Randomized Trials. American Journal of Kidney Diseases, 2014, 64, 32-39.	2.1	89
138	Distinguishing between early and late responders to symptoms of acute myocardial infarction. American Journal of Cardiology, 1995, 75, 1019-1022.	0.7	88
139	Stroke and acute Myocardial Infarction in the Thrombolytic era: Clinical correlates and long-term prognosis. Journal of the American College of Cardiology, 1990, 16, 533-540.	1.2	87
140	Impact of an interactive video on decision making of patients with ischemic heart disease. Journal of General Internal Medicine, 1996, 11, 373-376.	1.3	86
141	Clinical Data Bases. Medical Care, 1985, 23, 623-647.	1.1	85
142	B-Type Natriuretic Peptide â€" A Biomarker for All Seasons?. New England Journal of Medicine, 2004, 350, 718-720.	13.9	85
143	Estimating the likelihood of severe coronary artery disease. American Journal of Medicine, 1991, 90, 553-562.	0.6	83
144	Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus. American Heart Journal, 2005, 149, 434-443.	1.2	82

#	Article	IF	CITATIONS
145	Impact of rate-modulated pacing on quality of life and exercise capacityâ€"Evidence from the Advanced Elements of Pacing Randomized Controlled Trial (ADEPT). Heart Rhythm, 2007, 4, 1125-1132.	0.3	82
146	Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy. JAMA Cardiology, 2017, 2, 685.	3.0	82
147	Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: Mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). American Heart Journal, 2007, 153, 573-578.	1.2	81
148	Identification of Patients With Stable Chest Pain Deriving Minimal Value From Noninvasive Testing. JAMA Cardiology, 2017, 2, 400.	3.0	80
149	Effect of smoking and sedentary behavior on the association between depressive symptoms and mortality from coronary heart disease. American Journal of Cardiology, 2003, 92, 529-532.	0.7	79
150	Female Gender Is Associated With Impaired Quality of Life 1 Year After Coronary Artery Bypass Surgery. Psychosomatic Medicine, 2003, 65, 944-951.	1.3	77
151	Primary Prevention with Defibrillator Therapy in Women: Results from the Sudden Cardiac Death in Heart Failure Trial. Journal of Cardiovascular Electrophysiology, 2008, 19, 720-724.	0.8	77
152	Sex Differences in Functional and CTÂAngiography Testing in Patients With Suspected Coronary Artery Disease. Journal of the American College of Cardiology, 2016, 67, 2607-2616.	1.2	75
153	Perceived Social Support as a Predictor of Mortality in Coronary Patients: Effects of Smoking, Sedentary Behavior, and Depressive Symptoms. Psychosomatic Medicine, 2005, 67, 40-45.	1.3	74
154	The Effect of an EDTA-based Chelation Regimen on Patients With Diabetes Mellitus and Prior Myocardial Infarction in the Trial to Assess Chelation Therapy (TACT). Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 15-24.	0.9	74
155	Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial. JAMA Cardiology, 2020, 5, 757.	3.0	74
156	Catheter Ablation for Ventricular Tachycardia in Patients with an Implantable Cardioverter Defibrillator (CALYPSO) Pilot Trial. Journal of Cardiovascular Electrophysiology, 2015, 26, 151-157.	0.8	73
157	Painless exercise ST deviation on the treadmill: Long-term prognosis. Journal of the American College of Cardiology, 1989, 14, 885-892.	1.2	72
158	Assessing the Clinical and Economic Burden of Coronary Artery Disease: 1986-1998. Medical Care, 2001, 39, 824-835.	1.1	72
159	Outcomes of Implantable Cardioverter-Defibrillator Use in Patients With Comorbidities. JACC: Heart Failure, 2014, 2, 623-629.	1.9	72
160	A simplified method to predict occurrence of complete heart block during acute myocardial infarction. American Journal of Cardiology, 1986, 57, 1213-1219.	0.7	71
161	Long-Term Mortality of Patients With Acute Myocardial Infarction in the United States and Canada. Circulation, 2004, 110, 1754-1760.	1.6	70
162	Tying clinical research to patient care by use of an observational database. Statistics in Medicine, 1984, 3, 375-384.	0.8	69

#	Article	IF	CITATIONS
163	Medical, psychological and social correlates of work disability among men with Coronary artery disease. American Journal of Cardiology, 1986, 58, 911-915.	0.7	68
164	Design of the Trial to Assess Chelation Therapy (TACT). American Heart Journal, 2012, 163, 7-12.	1.2	68
165	Impact of Lung Transplantation on Recipient Quality of Life. Chest, 2013, 143, 744-750.	0.4	66
166	NT-proBNP Goal Achievement IsÂAssociated With Significant ReverseÂRemodeling and Improved Clinical Outcomes in HFrEF. JACC: Heart Failure, 2019, 7, 158-168.	1.9	65
167	Helicopter transport of patients during acute myocardial infarction. American Journal of Cardiology, 1988, 61, 718-722.	0.7	64
168	Poverty, process of care, and outcome in acute coronary syndromes. Journal of the American College of Cardiology, 2003, 41, 1948-1954.	1.2	64
169	International differences in evolution of early discharge after acute myocardial infarction. Lancet, The, 2004, 363, 511-517.	6.3	64
170	Recovery Expectations and Long-term Prognosis of Patients With Coronary Heart Disease. Archives of Internal Medicine, 2011, 171, 929-35.	4.3	64
171	Localizing Coronary Artery Obstructions with the Exercise Treadmill Test. Annals of Internal Medicine, 1987, 106, 53.	2.0	63
172	Facets of Openness Predict Mortality in Patients With Cardiac Disease. Psychosomatic Medicine, 2007, 69, 319-322.	1.3	63
173	Adoption of thrombolytic therapy in the management of acute myocardial infarction. American Journal of Cardiology, 1988, 61, 510-514.	0.7	62
174	Prognostic value of the simplified selvester QRS score in patients with coronary artery disease. Journal of the American College of Cardiology, 1988, 11, 35-41.	1.2	61
175	Association between bleeding, blood transfusion, and costs among patients with non–ST-segment elevation acute coronary syndromes. American Heart Journal, 2008, 155, 369-374.	1.2	61
176	Rapid-Rate Nonsustained Ventricular Tachycardia Found on Implantable Cardioverter-Defibrillator Interrogation. Journal of the American College of Cardiology, 2013, 61, 2161-2168.	1.2	60
177	Differences in the Treatment of Myocardial Infarction Between the United States and Canada. Medical Care, 1995, 33, 598-610.	1.1	59
178	Perception of cognitive function in older adults following coronary artery bypass surgery Health Psychology, 1999, 18, 301-306.	1.3	59
179	Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: Randomized trial evidence through 2004. American Heart Journal, 2005, 149, 1020-1034.	1.2	59
180	Trends in physician management of uncomplicated acute myocardial infarction, 1970 to 1987. American Journal of Cardiology, 1988, 61, 515-518.	0.7	58

#	Article	IF	Citations
181	An ECG index of myocardial scar enhances prediction of defibrillator shocks: An analysis of the Sudden Cardiac Death in Heart Failure Trial. Heart Rhythm, 2011, 8, 38-45.	0.3	58
182	Quality-of-Life Outcomes With Coronary Artery Bypass Graft Surgery in Ischemic Left Ventricular Dysfunction. Annals of Internal Medicine, 2014, 161, 392.	2.0	58
183	Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization. Circulation, 2016, 133, 39-47.	1.6	58
184	MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS. , 1996, 15, 361.		58
185	Clinical judgement and therapeutic decision making. Journal of the American College of Cardiology, 1990, 15, 1-14.	1.2	57
186	Electrocardiographic Differentiation of the ST-Segment Depression of Acute Myocardial Injury Due to the Left Circumflex Artery Occlusion from that of Myocardial Ischemia of Nonocclusive Etiologies. American Journal of Cardiology, 1997, 80, 512-513.	0.7	57
187	Acute and long-term cost implications of coronary stenting. Journal of the American College of Cardiology, 1999, 33, 1610-1618.	1.2	57
188	AHA Science Advisory. Progress in Cardiovascular Nursing, 2009, 24, 19-26.	0.5	57
189	Economic Outcomes With Anatomical Versus Functional Diagnostic Testing for Coronary Artery Disease. Annals of Internal Medicine, 2016, 165, 94.	2.0	57
190	Ratings of positive and depressive emotion as predictors of mortality in coronary patients. International Journal of Cardiology, 2005, 100, 213-216.	0.8	56
191	Design and methodology of the Occluded Artery Trial (OAT). American Heart Journal, 2005, 150, 627-642.	1.2	56
192	No benefit of a dual coil over a single coil ICD lead: Evidence from the Sudden Cardiac Death in Heart Failure Trial. Heart Rhythm, 2013, 10, 970-976.	0.3	56
193	Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease. New England Journal of Medicine, 2020, 382, 1619-1628.	13.9	56
194	Rethinking sensitivity and specificity. American Journal of Cardiology, 1987, 59, 1195-1198.	0.7	54
195	Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). American Heart Journal, 2008, 155, 501-506.	1.2	54
196	Intraoperative Magnesium Administration Does Not Improve Neurocognitive Function After Cardiac Surgery. Stroke, 2013, 44, 3407-3413.	1.0	54
197	Natriuretic Peptide Response and Outcomes in Chronic HeartÂFailure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 1205-1217.	1.2	54
198	Understanding the Role of $\langle i \rangle P \langle  i \rangle$ Values and Hypothesis Tests in Clinical Research. JAMA Cardiology, 2016, 1, 1048.	3.0	53

#	Article	IF	CITATIONS
199	Effects of Coronary Angioplasty, Coronary Bypass Surgery, and Medical Therapy on Employment in Patients with Coronary Artery Disease: A Prospective Comparison Study. Annals of Internal Medicine, 1994, 120, 111.	2.0	52
200	Clinical correlates of the initial and long-term cost of coronary bypass surgery and coronary angioplasty. American Heart Journal, 1999, 138, 376-383.	1.2	52
201	ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 Expert Consensus Document on Coronary Computed Tomographic Angiography. Catheterization and Cardiovascular Interventions, 2010, 76, E1-42.	0.7	51
202	Treatment with Adenosine Diphosphate Receptor Inhibitorsâ€"Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study design: Expanding the paradigm of longitudinal observational research. American Heart Journal, 2011, 162, 844-851.	1.2	51
203	Oral High-Dose Multivitamins and Minerals After Myocardial Infarction. Annals of Internal Medicine, 2013, 159, 797.	2.0	51
204	Stress Testing Versus CT Angiography inÂPatients With Diabetes and SuspectedÂCoronary Artery Disease. Journal of the American College of Cardiology, 2019, 73, 893-902.	1.2	51
205	The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure. American Heart Journal, 2014, 167, 193-202.e1.	1.2	50
206	Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction. JAMA Cardiology, 2017, 2, 750.	3.0	50
207	Late restenosis after emergent coronary angioplasty for acute myocardial infarction: Comparison with elective coronary angioplasty. Journal of the American College of Cardiology, 1988, 11, 698-705.	1.2	48
208	Clinical and research issues regarding chronic advanced coronary artery disease Part II: Trial design, outcomes, and regulatory issues. American Heart Journal, 2008, 155, 435-444.	1.2	48
209	Medical Economics and the Assessment of Value in Cardiovascular Medicine: Part II. Circulation, 2002, 106, 626-630.	1.6	47
210	Myocardial infarction following coronary artery bypass graft surgery increases healthcare resource utilization. Critical Care Medicine, 2007, 35, 1296-1301.	0.4	47
211	ACC/AHA/ASE/ASNC/HRS/IAC/Mended Hearts/NASCI/RSNA/SAIP/SCAI/SCCT/SCMR/SNMMI 2014 Health Policy Statement on Use of Noninvasive Cardiovascular Imaging. Journal of the American College of Cardiology, 2014, 63, 698-721.	1.2	47
212	Association Between Sex and Treatment Outcomes of Atrial Fibrillation Ablation Versus Drug Therapy. Circulation, 2021, 143, 661-672.	1.6	47
213	Obesity and Longâ€Term Clinical and Economic Outcomes in Coronary Artery Disease Patients. Obesity, 2002, 10, 83-91.	4.0	46
214	Hostility, Age, and Mortality in a Sample of Cardiac Patients. American Journal of Cardiology, 2005, 96, 64-66.	0.7	46
215	Preventing tomorrow's sudden cardiac death today. American Heart Journal, 2008, 156, 613-622.	1.2	46
216	Ejection fraction assessment and survival: An analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). American Heart Journal, 2008, 156, 1196-1200.	1.2	46

#	Article	IF	CITATIONS
217	Assessment of activity status and survival according to the Canadian Cardiovascular Society angina classification. Canadian Journal of Cardiology, 2009, 25, e225-e231.	0.8	46
218	Acute and 1‥ear Hospitalization Costs for Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention: ResultsÂFrom the TRANSLATEâ€ACS Registry. Journal of the American Heart Association, 2019, 8, e011322.	1.6	45
219	The Relationship between Self-Rated Health and Health Status among Coronary Artery Patients. Journal of Aging and Health, 1999, 11, 565-584.	0.9	44
220	A New Anatomic Score for Prognosis After Cardiac Catheterization in Patients with Previous Bypass Surgery. Journal of the American College of Cardiology, 2005, 46, 1684-1692.	1.2	44
221	The high cost of implantable defibrillators. European Heart Journal, 2007, 28, 388-391.	1.0	44
222	Reporting and representation of race/ethnicity in published randomized trials. American Heart Journal, 2009, 158, 742-747.	1.2	44
223	The External Validity of Prediction Models for the Diagnosis of Obstructive CoronaryÂArtery Disease in Patients WithÂStable Chest Pain. JACC: Cardiovascular Imaging, 2018, 11, 437-446.	2.3	44
224	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches–Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design. American Heart Journal, 2018, 205, 42-52.	1.2	44
225	Association Between Age and Outcomes of Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: Results From the CABANA Trial. Circulation, 2022, 145, 796-804.	1.6	44
226	Protecting the Brain in Coronary Artery Bypass Graft Surgery. JAMA - Journal of the American Medical Association, 2002, 287, 1448.	3.8	43
227	Clinical and research issues regarding chronic advanced coronary artery disease. American Heart Journal, 2008, 155, 418-434.	1.2	43
228	Exercise Capacity and Mortality in Patients With Ischemic Left Ventricular Dysfunction Randomized to Coronary Artery Bypass Graft Surgery or Medical Therapy. JACC: Heart Failure, 2014, 2, 335-343.	1.9	43
229	Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy inÂtheÂSCD-HeFT. Journal of the American College of Cardiology, 2020, 76, 405-415.	1.2	43
230	Feasibility and cost-saving potential of outpatient cardiac catheterization. Journal of the American College of Cardiology, 1990, 15, 378-384.	1.2	42
231	Impact of Early Discharge After Coronary Artery Bypass Graft Surgery on Rates of Hospital Readmission and Death fn1fn1This study was supported by Research Grants HS-06503 and HS-08805-02 from the Agency for Health Care Policy and Research, Rockville, Maryland and was presented in part at the 45th Annual Scientific Session of the American College of Cardiology, Orlando, Florida, March	1.2	42
232	1996. Journal of the American College of Cardiology, 1997, 30, 908-913.  Task force #5â€"is atherosclerosis imaging cost effective?. Journal of the American College of Cardiology, 2003, 41, 1906-1917.	1.2	42
233	Usefulness of a pericardial friction rub after thrombolytic therapy during acute myocardial infarction in predicting amount of myocardial damage. American Journal of Cardiology, 1990, 66, 1418-1421.	0.7	40
234	Cost-Effectiveness of Follow-Up of Pulmonary Nodules Incidentally Detected on Cardiac Computed Tomographic Angiography in Patients With Suspected Coronary Artery Disease. Circulation, 2014, 130, 668-675.	1.6	40

#	Article	IF	CITATIONS
235	Assessing quality-of-life outcomes in cardiovascular clinical research. Nature Reviews Cardiology, 2016, 13, 286-308.	6.1	40
236	Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 2302-2309.e6.	0.4	40
237	Variant angina and spontaneous coronary artery dissection. American Journal of Cardiology, 1985, 56, 485-486.	0.7	39
238	Implantable Cardioverter Defibrillator Therapy in Patients with Prior Coronary Revascularization in the Sudden Cardiac Death in Heart Failure Trial (SCDâ€HeFT). Journal of Cardiovascular Electrophysiology, 2008, 19, 1059-1065.	0.8	38
239	Prediction of early recurrent myocardial ischemia and coronary reocclusion after successful thrombolysis: A qualitative and quantitative angiographic study. American Journal of Cardiology, 1989, 63, 423-428.	0.7	37
240	Economics of Treating Heart Failure. American Journal of Cardiology, 1997, 80, 33H-38H.	0.7	37
241	Variability in cost of coronary bypass surgery in New York State: Potential for cost savings. American Heart Journal, 2002, 143, 130-139.	1.2	37
242	Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Heart Rhythm, 2011, 8, 393-400.	0.3	37
243	Economic impact of drug-eluting stents on hospital systems: a disease-state model. American Heart Journal, 2004, 147, 449-456.	1.2	36
244	Clinical factors related to morbidity and mortality in highâ€risk heart failure patients: the GUIDEâ€IT predictive model and risk score. European Journal of Heart Failure, 2019, 21, 770-778.	2.9	36
245	Geographic Variation in Resource Use for Coronary Artery Bypass Surgery. Medical Care, 1997, 35, 320-333.	1.1	36
246	Cost Effectiveness of Inpatient Initiation of Antiarrhythmic Therapy for Supraventricular Tachycardias. American Journal of Cardiology, 1997, 80, 1551-1557.	0.7	35
247	A comparison of U.S. and Canadian cardiac catheterization practices in detecting severe coronary artery disease after myocardial infarction: efficiency, yield and long-term implications. Journal of the American College of Cardiology, 1999, 34, 12-19.	1.2	35
248	Association Between Prophylactic Implantable Cardioverter-Defibrillators and Survival in Patients With Left Ventricular Ejection Fraction Between 30% and 35%. JAMA - Journal of the American Medical Association, 2014, 311, 2209.	3.8	35
249	Quality-of-Life Outcomes With Anatomic Versus Functional Diagnostic Testing Strategies in Symptomatic Patients With Suspected Coronary Artery Disease. Circulation, 2016, 133, 1995-2007.	1.6	35
250	New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials. American Heart Journal, 2017, 191, 21-29.	1.2	35
251	Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute Myocardial Infarction. American Journal of Cardiology, 1995, 76, 1007-1013.	0.7	34
252	Moderators of the effect of social support on depressive symptoms in cardiac patients. American Journal of Cardiology, 2000, 86, 438-442.	0.7	34

#	Article	IF	Citations
253	Quality of Life after Late Invasive Therapy for Occluded Arteries. New England Journal of Medicine, 2009, 360, 774-783.	13.9	34
254	Long-Term Effects of Percutaneous Coronary Intervention of the Totally Occluded Infarct-Related Artery in the Subacute Phase After Myocardial Infarction. Circulation, 2011, 124, 2320-2328.	1.6	34
255	EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy. American Heart Journal, 2014, 168, 37-44.e5.	1.2	34
256	Unexpected Deviation in Circadian Variation ofÂVentricular Arrhythmias. Journal of the American College of Cardiology, 2014, 63, 2702-2708.	1.2	34
257	Changes in Medical Therapy and Lifestyle After Anatomical or Functional Testing for Coronary Artery Disease. Journal of the American Heart Association, 2016, 5, .	1.6	34
258	Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: Results from the Surgical Treatment for Ischemic Heart Failure trial. American Heart Journal, 2009, 157, 837-844.e3.	1.2	33
259	2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, e23-e106.	0.4	33
260	Absence of bilateral vision loss from amiodarone: A randomized trial. American Heart Journal, 2007, 153, 837-842.	1.2	32
261	Cost-effectiveness Analysis of Anatomic vs Functional Index Testing in Patients With Low-Risk Stable Chest Pain. JAMA Network Open, 2020, 3, e2028312.	2.8	32
262	Outcomes and costs within a disease management program for advanced congestive heart failure. American Heart Journal, 1998, 135, S285-S292.	1.2	31
263	Economic Assessment of Platelet Glycoprotein IIb/IIIa Receptor Blockade With Abciximab and Low-Dose Heparin During Percutaneous Coronary Revascularization. Circulation, 2000, 102, 2923-2929.	1.6	31
264	Prospective Study of Perceived Stress in Cardiac Patients. Annals of Behavioral Medicine, 2004, 27, 22-30.	1.7	31
265	Is Early Too Early? Effect of Shorter Stays After Bypass Surgery. Annals of Thoracic Surgery, 2007, 83, 100-107.	0.7	31
266	Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors., 2005,, 223-249.		30
267	Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: Results from the Treating to New Targets (TNT) Trial. American Heart Journal, 2008, 156, 698-705.	1.2	30
268	Economic Analysis of Ticagrelor Therapy From a U.S. Perspective. Journal of the American College of Cardiology, 2015, 65, 465-476.	1.2	30
269	Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women. JACC: Heart Failure, 2015, 3, 159-167.	1.9	30
270	Comparison of visual assessment of coronary stenosis with independent quantitative coronary angiography: Findings from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial. American Heart Journal, 2017, 184, 1-9.	1.2	30

#	Article	IF	CITATIONS
271	Advanced coronary artery disease: Appropriate end points for trials of novel therapies. American Heart Journal, 2001, 142, 843-851.	1.2	29
272	Impact of Residency Status on Perfusion Times and Outcomes for Coronary Artery Bypass Graft Surgery. Annals of Thoracic Surgery, 2007, 83, 2103-2110.	0.7	29
273	Empirical estimation of life expectancy from large clinical trials: Use of leftâ€truncated, rightâ€censored survival analysis methodology. Statistics in Medicine, 2008, 27, 5525-5555.	0.8	29
274	Cardiovascular disease on a global scale: defining the path forward for research and practice. European Heart Journal, 2007, 28, 2678-2684.	1.0	28
275	Ablation Versus Drug Therapy for Atrial Fibrillation in Racial and Ethnic Minorities. Journal of the American College of Cardiology, 2021, 78, 126-138.	1.2	28
276	Where patients with mild to moderate heart failure die: Results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). American Heart Journal, 2007, 153, 1089-1094.	1.2	27
277	Quality of life in patients with implantable cardioverter–defibrillator: systematic review of randomized controlled trials. European Journal of Cardiovascular Nursing, 2018, 17, 196-206.	0.4	27
278	Predictive Model for High-Risk Coronary Artery Disease. Circulation: Cardiovascular Imaging, 2019, 12, e007940.	1.3	27
279	Pericardial effusion after intravenous recombinant tissue-type plasminogen activator for acute myocardial infarction. American Journal of Cardiology, 1991, 67, 496-500.	0.7	26
280	Trends in postoperative length of stay after bypass surgery. American Heart Journal, 2006, 152, 1194-1200.	1.2	26
281	Better functional status in American than Canadian patients with heart disease: An effect of medical care?. Journal of the American College of Cardiology, 1995, 26, 1115-1120.	1.2	25
282	Do Income Level and Race Influence Survival in Patients Receiving Hemodialysis?. American Journal of Medicine, 2009, 122, 170-180.	0.6	25
283	The Impact of New and Emerging Clinical Data on Treatment Strategies for Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2010, 21, 946-958.	0.8	25
284	SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death. Heart Rhythm, 2015, 12, 2058-2066.	0.3	25
285	Use of Evidence-Based Medical Therapy in Patients Undergoing Percutaneous Coronary Revascularization in the United States, Europe, and Canada. American Journal of Cardiology, 1997, 79, 867-872.	0.7	24
286	The Chest-Pain Unit — Ready for Prime Time?. New England Journal of Medicine, 1998, 339, 1930-1932.	13.9	24
287	Effects of Stroke on Medical Resource Use and Costs in Acute Myocardial Infarction. Circulation, 1999, 99, 370-376.	1.6	24
288	Safety of coronary CT angiography and functional testing for stable chest pain in the PROMISE trial: A randomized comparison of test complications, incidental findings, and radiation dose. Journal of Cardiovascular Computed Tomography, 2017, 11, 373-382.	0.7	24

#	Article	IF	CITATIONS
289	Implantable cardioverterâ€defibrillators in heart failure patients with reduced ejection fraction and diabetes. European Journal of Heart Failure, 2018, 20, 1031-1038.	2.9	24
290	Atrial fibrillation burden and heart failure: Data from 39,710 individuals with cardiac implanted electronic devices. Heart Rhythm, 2021, 18, 709-716.	0.3	24
291	Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure. American Heart Journal, 2006, 152, 974.e7-974.e11.	1.2	23
292	Baseline and 6-month costs of primary angioplasty therapy for acute myocardial infarction: Results from the primary angioplasty registry. Journal of the American College of Cardiology, 1995, 26, 688-695.	1.2	22
293	Implications of cost in treatment selection for patients with coronary heart disease. Annals of Thoracic Surgery, 1996, 61, s12-s15.	0.7	22
294	Sex Bias in Cardiovascular Care. JAMA - Journal of the American Medical Association, 2000, 283, 659.	3.8	22
295	Using observational data to estimate prognosis: an example using a coronary artery disease registry. Statistics in Medicine, 2001, 20, 2505-2532.	0.8	22
296	The Economics of Heart Failure. Heart Failure Clinics, 2013, 9, 93-106.	1.0	22
297	Administration of thrombolytic therapy in the community hospital: Established principles and unresolved issues. Journal of the American College of Cardiology, 1988, 12, A32-A43.	1.2	21
298	Task Force #2â€"the cost of prevention: can we afford it? Can we afford not to do it?. Journal of the American College of Cardiology, 2002, 40, 603-615.	1.2	21
299	Prospective Study of Associations Among Positive Emotion and Functional Status in Older Patients With Coronary Artery Disease. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2009, 64B, 461-469.	2.4	21
300	Revascularization in stable coronary disease: evidence and uncertainties. Nature Reviews Cardiology, 2018, 15, 408-419.	6.1	21
301	Economic Implications of the Prophylactic Use of Intraaortic Balloon Counterpulsation in the Setting of Acute Myocardial Infarction. American Journal of Cardiology, 1997, 79, 590-594.	0.7	20
302	Temperature during coronary artery bypass surgery affects quality of life. Annals of Thoracic Surgery, 2001, 71, 110-116.	0.7	20
303	Planning the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a Collaborative Pan-Stakeholder Critical Path Registry Model: A Cardiac Safety Research Consortium "Incubator― Think Tank. American Heart Journal, 2010, 159, 17-24.e1.	1.2	20
304	Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for HeartÂFailure. Journal of the American College of Cardiology, 2018, 72, 2551-2562.	1.2	20
305	Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial. American Heart Journal, 2019, 208, 28-36.	1.2	20
306	Long-term outcomes of mitral regurgitation by type and severity. American Heart Journal, 2018, 203, 39-48.	1.2	19

#	Article	IF	Citations
307	Clinical correlates and prognostic significance of type A behavior and silent myocardial ischemia on the treadmill. American Journal of Cardiology, 1989, 64, 1280-1283.	0.7	18
308	The way of the future redux. American Journal of Cardiology, 1995, 76, 1177-1182.	0.7	18
309	Quality of life after coronary revascularization in the United States and Canada. American Journal of Cardiology, 2000, 85, 548-553.	0.7	18
310	Prognostic value of predischarge electrocardiographic measurement of infarct size after thrombolysis: Insights from GUSTO I Economics and Quality of Life substudy. American Heart Journal, 2004, 148, 795-802.	1.2	18
311	Use of the 6-Min Walk Distance to IdentifyÂVariations in Treatment Benefits FromÂImplantable Cardioverter-Defibrillator andÂAmiodarone. Journal of the American College of Cardiology, 2014, 63, 2560-2568.	1.2	18
312	Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective. JAMA Cardiology, 2017, 2, 525.	3.0	18
313	Predicting appropriate shocks in patients with heart failure: Patient level metaâ€analysis from SCDâ€HeFT and MADIT II. Journal of Cardiovascular Electrophysiology, 2017, 28, 1345-1351.	0.8	18
314	Implications of Abnormal Exercise Electrocardiography With Normal Stress Echocardiography. JAMA Internal Medicine, 2020, 180, 494.	2.6	18
315	Surrogate assessment of coronary artery disease patients' functional capacity. Social Science and Medicine, 1997, 44, 1491-1502.	1.8	17
316	The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trial to Assess Chelation Therapy (TACT). Journal of Diabetes and Its Complications, 2019, 33, 490-494.	1.2	17
317	Off-Pump Bypass Surgeryâ€"Ready for the Big Dance?. JAMA - Journal of the American Medical Association, 2004, 291, 1897.	3.8	16
318	Cosmetics, Regulations, and the Public Health. JAMA Internal Medicine, 2017, 177, 1080.	2.6	16
319	Predictors of Outcome and the Lack of Effect of Percutaneous Coronary Intervention Across the Risk Strata in Patients With Persistent Total Occlusion After Myocardial Infarction. JACC: Cardiovascular Interventions, 2008, 1, 511-520.	1.1	15
320	Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: Costs of reperfusion strategies in acute myocardial infarction. American Heart Journal, 2005, 149, 637-644.	1.2	14
321	Long-term Clinical Outcomes Following Coronary Stenting. Archives of Internal Medicine, 2008, 168, 1647.	4.3	14
322	Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus. Journal of the American College of Cardiology, 2017, 69, 2304-2313.	1.2	14
323	Palliative care and hospital readmissions in patients with advanced heart failure: Insights from the PAL-HF trial. American Heart Journal, 2018, 204, 202-204.	1.2	14
324	Strategies for Incorporating Resource Allocation and Economic Considerations. Chest, 2008, 133, 132S-140S.	0.4	14

#	Article	IF	CITATIONS
325	Arrhythmic Burden and the Risk of Cardiovascular Outcomes in Patients With Paroxysmal Atrial Fibrillation and Cardiac Implanted Electronic Devices. Circulation: Arrhythmia and Electrophysiology, 2022, 15, CIRCEP121010304.	2.1	14
326	Personality and coping with a common stressor: cardiac catheterization. Journal of Behavioral Medicine, 2001, 24, 17-31.	1.1	13
327	Exploring options for improving healthcare. American Heart Journal, 2004, 147, 23-30.	1.2	13
328	Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: Does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. Heart Rhythm, 2013, 10, 828-835.	0.3	13
329	Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial. European Heart Journal, 2022, 43, 148-149.	1.0	13
330	The prospective randomized trial of the optimal evaluation of cardiac symptoms and revascularization: Rationale and design of the PRECISE trial. American Heart Journal, 2022, 245, 136-148.	1.2	13
331	The trial to assess chelation therapy 2 (TACT2): Rationale and design. American Heart Journal, 2022, 252, 1-11.	1.2	13
332	Fundamentals of economic analysis. American Heart Journal, 1999, 137, S38-S40.	1.2	12
333	Evaluating the Potential ???Economic Attractiveness??? of New Therapies in Patients with Non-ST Elevation Acute Coronary Syndrome. Pharmacoeconomics, 2000, 17, 263-272.	1.7	12
334	Impact of Diabetes Mellitus on the Evaluation of Stable Chest Pain Patients: Insights From the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) Trial. Journal of the American Heart Association, 2017, 6, .	1.6	12
335	Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates. JACC: Clinical Electrophysiology, 2018, 4, 1089-1102.	1.3	12
336	Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: Results from the IMPRESS trial. American Heart Journal, 2002, 143, 1112-1117.	1.2	11
337	Rationale and design of the Home Automatic External Defibrillator Trial (HAT). American Heart Journal, 2008, 155, 445-454.	1.2	11
338	Careers for Clinician Investigators. Circulation, 2009, 119, 2945-2950.	1.6	11
339	Assessing the Economic Attractiveness of Coronary Artery Revascularization in Chronic Kidney Disease Patients. Journal of Medical Systems, 2009, 33, 287-297.	2.2	11
340	How Reliable are Patientâ€Reported Rehospitalizations? Implications for the Design of Future Practical Clinical Studies. Journal of the American Heart Association, 2016, 5, .	1.6	11
341	PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability. JAMA - Journal of the American Medical Association, 2017, 318, 711.	3.8	11
342	Comprehensive Quality-of-Life Outcomes With Invasive Versus Conservative Management of Chronic Coronary Disease in ISCHEMIA. Circulation, 2022, 145, 1294-1307.	1.6	11

#	Article	IF	CITATIONS
343	Early Post-Discharge Bleeding and Antiplatelet Therapy Discontinuation Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2014, 63, 1700-1702.	1.2	10
344	Intracranial hemorrhage risk and new thrombolytic therapies in acute myocardial infarction. American Journal of Cardiology, 1994, 73, 444-449.	0.7	9
345	Correlations Between Preprocedure Mood and Clinical Outcome in Patients Undergoing Coronary Angioplasty. Cardiology in Review, 2003, 11, 309-317.	0.6	9
346	Drone-Based Automatic External Defibrillators for Sudden Death?. Circulation, 2017, 135, 2466-2469.	1.6	9
347	African Americans With Advanced Heart Failure Are More Likely to Die in a Health Care Facility Than at Home or in Hospice: An Analysis From the PAL-HF Trial. Journal of Cardiac Failure, 2019, 25, 693-694.	0.7	9
348	Discordances between predicted and actual risk in obese patients with suspected cardiac ischaemia. Heart, 2020, 106, 273-279.	1.2	9
349	Treatment-Related Changes in Left Atrial Structure in Atrial Fibrillation: Findings From the CABANA Imaging Substudy. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e008540.	2.1	9
350	Influence of atrial fibrillation type on outcomes of ablation vs. drug therapy: results from CABANA. Europace, 2022, 24, 1430-1440.	0.7	9
351	Angina, myocardial ischemia and coronary disease: Gold standards, operational definitions and correlations. Journal of Clinical Epidemiology, 1989, 42, 381-384.	2.4	8
352	An overview of risk assessment in coronary artery disease. American Journal of Cardiology, 1994, 73, B19-B25.	0.7	8
353	Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial). American Journal of Cardiology, 2000, 86, 24-29.	0.7	8
354	What Is the Economic Value of Digoxin Therapy in Congestive Heart Failure Patients? Results From the DIG Trial. Journal of Cardiac Failure, 2006, 12, 336-342.	0.7	8
355	Relationship of female sex to outcomes after myocardial infarction with persistent total occlusion of the infarct artery: Analysis of the Occluded Artery Trial (OAT). American Heart Journal, 2012, 163, 462-469.	1.2	8
356	Quality-of-Life Outcomes With a Disodium EDTA Chelation Regimen for Coronary Disease. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 508-516.	0.9	8
357	Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	8
358	ISCHEMIA trial update. American Heart Journal, 2019, 218, 8.	1.2	8
359	Fixing the Heart. Circulation, 2004, 110, 3402-3403.	1.6	7
360	Noninvasive imaging for coronary artery disease: A technology assessment for the Medicare Coverage Advisory Commission. American Heart Journal, 2007, 153, 161-174.	1.2	7

#	Article	IF	CITATIONS
361	Downstream Testing and Subsequent Procedures After Coronary Computed Tomographic Angiography Following Coronary Stenting in Patients ≥65 Years of Age. American Journal of Cardiology, 2012, 110, 776-783.	0.7	7
362	Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy—Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value. JAMA Cardiology, 2017, 2, 1066.	3.0	7
363	Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Medicine in Ischemic Cardiomyopathy: The STICH Randomized Clinical Trial. Circulation, 2022, 145, 819-828.	1.6	7
364	The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. American Heart Journal, 1999, 137, S90-S93.	1.2	6
365	Navigating the scylla and charybdis of chest pain management in the emergency department American Journal of Medicine, 2002, 112, 154-156.	0.6	6
366	Development and validation of a simple model to predict severe coronary artery disease after myocardial infarction: Potential impact on cardiac catheterization use in the United States and Canada. American Heart Journal, 2003, 145, 349-355.	1.2	6
367	Effects of obesity on noninvasive test results in patients with suspected cardiac ischemia: Insights from the PROMISE trial. Journal of Cardiovascular Computed Tomography, 2019, 13, 211-218.	0.7	6
368	Clinical and Economic Lessons from Studies of Coronary Thrombolysis. Journal of Vascular and Interventional Radiology, 1995, 6, 94S-101S.	0.2	5
369	Cost estimates for treatment of cardiac ischemia (from the Asymptomatic Cardiac Ischemia Pilot [ACIP]) Tj ETQq1	1.0.7843	1 <sub>5</sub> 4 rgBT /O
370	Use of abciximab: Comparative economic data. American Heart Journal, 1999, 137, S123-S125.	1.2	5
371	Risk stratification in patients with chest pain. Primary Care - Clinics in Office Practice, 2001, 28, 99-118.	0.7	5
372	Intracoronary Brachytherapy. Circulation, 2002, 106, 646-648.	1.6	5
373	Early hospital discharge after uncomplicated myocardial infarction: are further improvements possible? European Heart Journal, 2003, 24, 1613-1615.	1.0	5
374	AB19-5. Heart Rhythm, 2006, 3, S40.	0.3	5
375	Re-evaluating the volume–outcome relationship in hemodialysis patients. Health Policy, 2008, 88, 317-325.	1.4	5
376	Cardiac Computed Tomographic Angiography. Journal of the American College of Cardiology, 2010, 55, 1029-1031.	1.2	5
377	Pheochromocytoma Presenting as Fever of Unknown Origin. American Journal of Medicine, 2011, 124, e5-e6.	0.6	5
378	The Placement of Aortic Transcatheter Valve (PARTNER) Trial. Circulation, 2012, 125, 3243-3245.	1.6	5

#	Article	IF	CITATIONS
379	Quantifying sociodemographic and income disparities in medical therapy and lifestyle among symptomatic patients with suspected coronary artery disease: a cross-sectional study in North America. BMJ Open, 2017, 7, e016364.	0.8	5
380	Relationship Between Optimism and Outcomes in Patients With Chronic Angina Pectoris. American Journal of Cardiology, 2019, 123, 1399-1405.	0.7	5
381	Clinical and Economic Implications of Inconclusive Noninvasive Test Results in Stable Patients With Suspected Coronary Artery Disease. Circulation: Cardiovascular Imaging, 2020, 13, e009986.	1.3	5
382	Dapagliflozinâ€"Does Cost Make 4-Pillar Heart Failure Therapy Too Herculean a Labor for Medicine?. JAMA Cardiology, 2021, 6, 875.	3.0	5
383	Conservative Management of Acute Coronary Syndrome. Circulation, 2002, 105, 666-668.	1.6	5
384	Effect of type A behavior on exercise test outcome in coronary artery disease. American Journal of Cardiology, 1990, 66, 179-182.	0.7	4
385	Health Economics of Acute Coronary Syndromes. Journal of Thrombosis and Thrombolysis, 1998, 5, S161-S168.	1.0	4
386	Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: Lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists. American Heart Journal, 2002, 143, 594-601.	1.2	4
387	Quality still doesn't pay in heart failure management. Journal of Cardiac Failure, 2003, 9, 263-265.	0.7	4
388	Quality of life effects of automatic external defibrillators in the home: Results from the Home Automatic External Defibrillator Trial (HAT). American Heart Journal, 2010, 159, 627-634.e7.	1.2	4
389	Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator?. International Journal of Cardiology, 2014, 172, 253-254.	0.8	4
390	Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart disease. American Heart Journal, 1997, 134, s88-s96.	1.2	3
391	Trade-Offs and Toss-Ups. Journal of the American College of Cardiology, 2011, 58, 1566-1568.	1.2	3
392	Chelation Therapy and Cardiovascular Outcomesâ€"In Reply. JAMA - Journal of the American Medical Association, 2013, 310, 431.	3.8	3
393	Health-related quality of life outcomes with prasugrel among medically managed non–ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial. American Heart Journal. 2016. 178. 55-64.	1.2	3
394	Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT). American Heart Journal, 2018, 195, 70-77.	1.2	3
395	Design Considerations for UAV-Delivered Opioid Overdose Interventions. , 2019, , .		3
396	Possible differential benefits of edetate disodium in post-myocardial infarction patients with diabetes treated with different hypoglycemic strategies in the Trial to Assess Chelation Therapy (TACT). Journal of Diabetes and Its Complications, 2020, 34, 107616.	1.2	3

#	Article	IF	CITATIONS
397	Importance of Cost and Quality of Life in Decisions About Routine Angiography After Acute Myocardial Infarction. Circulation, 1996, 94, 869-871.	1.6	3
398	Assessing Quality of Life and Medical Care in Chronic Angina: An Internet Survey. Interactive Journal of Medical Research, 2016, 5, e12.	0.6	3
399	Association between economic and arrhythmic burden of paroxysmal atrial fibrillation in patients with cardiac implanted electronic devices. American Heart Journal, 2022, 244, 116-124.	1.2	3
400	The influence of comorbidities on achieving an Nâ€ŧerminal proâ€bâ€ŧype natriuretic peptide target: a secondary analysis of the GUIDEâ€∤T trial. ESC Heart Failure, 2021, , .	1.4	3
401	Race Differences in Quality of Life following a Palliative Care Intervention in Patients with Advanced Heart Failure: Insights from the Palliative Care in Heart Failure Trial. Journal of Palliative Medicine, 2022, 25, 296-300.	0.6	3
402	Physician judgement in predicting obstructive coronary artery disease and adverse events in chest pain patients. Heart, 2022, , heartjnl-2021-320275.	1.2	3
403	Presenting Symptoms in Patients Undergoing Coronary Artery Disease Evaluation: Association With Noninvasive Test Results and Clinical Outcomes in the PROMISE Trial. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, 101161CIRCOUTCOMES121008298.	0.9	3
404	Costs of Interventional Cardiac Procedures. Journal of Interventional Cardiology, 1994, 7, 369-378.	0.5	2
405	Coronary Catherization Patient and Wife's Perceptions of Social Support: Effects Due to Characteristics of Recipient, Provider, and Their Interaction. International Journal of Aging and Human Development, 2000, 50, 97-125.	1.0	2
406	Treating Sternal Wound Infections After Cardiac Surgery With an Implantable Gentamicin-Collagen Spongeâ€"Reply. JAMA - Journal of the American Medical Association, 2010, 304, 2123.	3.8	2
407	Cost-Effectiveness of Left Atrial Appendage Occlusion. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	2
408	Polypharmacy in Palliative Care for Advanced Heart Failure: The PAL-HF Experience. Journal of Cardiac Failure, 2022, 28, 334-338.	0.7	2
409	Abstract 18053: Prognostic Value of Anatomic versus Functional Diagnostic Testing in Symptomatic Patients With Suspected CAD: The PROMISE Trial (PROspective Multicenter Imaging Study for) Tj ETQq1 1 0.7843	3 <b>11.4</b> 6 rg BT /	Owerlock 10
410	Factors and outcomes associated with improved left ventricular systolic function in patients with cardiomyopathy. Cardiology Journal, 2022, 29, 978-984.	0.5	2
411	Differences in Cardiovascular Risk, Coronary Artery Disease, and Cardiac Events Between Black and White Individuals Enrolled in the PROMISE Trial. JAMA Cardiology, 2022, 7, 259.	3.0	2
412	Analysis of risk factors for sudden death after acute myocardial infarction. American Journal of Cardiology, 1985, 55, 621-622.	0.7	1
413	Economics and quality of life after acute myocardial infarction: Insights from GUSTO-I. Journal of Thrombosis and Thrombolysis, 1996, 3, 151-155.	1.0	1
414	Lessons for the editors. American Heart Journal, 1997, 134, 1-2.	1.2	1

#	Article	IF	Citations
415	Surgeons? Economic Profiles: Can We Get the ?Right? Answers?. Journal of Medical Systems, 2005, 29, 111-124.	2.2	1
416	Percutaneous coronary revascularisation: is it ever worth what it costs?. Heart, 2007, 93, 1161-1163.	1.2	1
417	Response to Letter Regarding Article, "Risk of Thromboembolism in Heart Failure: An Analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)― Circulation, 2008, 117, .	1.6	1
418	Response to Letters Regarding Article, "Role of Microvolt T-Wave Alternans in Assessment of Arrhythmia Vulnerability Among Patients With Heart Failure and Systolic Dysfunction: Primary Results From the T-Wave Alternans Sudden Cardiac Death in Heart Failure Trial Substudyâ€. Circulation, 2009, 120, .	1.6	1
419	Response to Letter Regarding Article, "Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure: Analysis From the Sudden Cardiac Death in Heart Failure Trial― Circulation, 2010, 122, .	1.6	1
420	Loss of short-term symptomatic benefit in patients with an occluded infarct artery is unrelated to non-protocol revascularization: Results from the Occluded Artery Trial (OAT). American Heart Journal, 2011, 161, 84-90.	1.2	1
421	Disodium EDTA Chelation for Post Myocardial Infarction Patients. Journal of Alternative and Complementary Medicine, 2014, 20, A2-A2.	2.1	1
422	Reply. Journal of the American College of Cardiology, 2014, 64, 1968-1969.	1.2	1
423	Coapting Cost and Clinical Outcomes in Transcatheter Intervention for Secondary Mitral Regurgitation. Circulation, 2019, 140, 1892-1894.	1.6	1
424	Differential Outcomes With Edetate Disodium-Based Treatment Among Stable Post Anterior vs. Non-Anterior Myocardial Infarction Patients. Cardiovascular Revascularization Medicine, 2020, 21, 1389-1395.	0.3	1
425	Patterns of Change in Individual Domains of the Kansas City Cardiomyopathy Questionnaire With a Palliative Care Intervention for Patients With Advanced Heart Failure: Insights from PAL-HF. Journal of Cardiac Failure, 2021, 27, 1476-1478.	0.7	1
426	Outcomes for Patients with Anterior Myocardial Infarction and Prior Cardiac Arrest in the Home Automated External Defibrillator Trial (HAT). Resuscitation, 2021, 168, 75-83.	1.3	1
427	Abstract 18819: Graded Benefit of EDTA Chelation in Post-MI Patients with Diabetes Treated with Different Hypoglycemic Strategies. Circulation, 2014, 130, .	1.6	1
428	Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy. Open Heart, 2018, 5, e000752.	0.9	1
429	Treating Myocardial Infarction in the Post-GUSTO Era. Pharmacoeconomics, 1996, 9, 473-477.	1.7	0
430	Economic impact of new interventional therapies. Journal of the American College of Cardiology, 2004, 44, 1809-1811.	1.2	0
431	Prognostic/Clinical Prediction Models: Using Observational Data to Estimate Prognosis: An Example Using a Coronary Artery Disease Registry., 2005,, 287-314.		0
432	Has American Heart Journal gone to the blogs?. American Heart Journal, 2009, 157, 955-956.	1.2	O

#	Article	IF	CITATIONS
433	Reply. Journal of the American College of Cardiology, 2013, 62, 2028-2029.	1.2	O
434	Patient-Reported Outcomes in Revascularization Decisions for Left-MainÂDisease. Journal of the American College of Cardiology, 2017, 70, 3123-3126.	1.2	0
435	CABANA: underpowered and with detrimental protocol changes: is †ablation salvation'?—Reply by the authors of the CABANA trial. Europace, 2022, 24, 3-3.	0.7	O
436	RISK STRATIFICATION IN PATIENTS WITH CHEST PAIN. Primary Care - Clinics in Office Practice, 1994, 21, 495-516.	0.7	0
437	Clinical Investigations Bimodal Distribution of Atrial Fibrillation Burden in 3 Distinct Cohorts: What is â€~Paroxysmal' Atrial Fibrillation?. American Heart Journal, 2021, 244, 149-149.	1.2	0